...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
【24h】

Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).

机译：合并高脂血症的辛伐他汀+非诺贝特治疗期间非高密度脂蛋白胆固醇和低密度脂蛋白胆固醇与载脂蛋白B的相关性（SAFARI试验的亚分析）。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Guidelines have recommended non-high-density lipoprotein (non-HDL) cholesterol as a secondary target for therapy after the low-density lipoprotein (LDL) cholesterol goals have been met in patients with hypertriglyceridemia; non-HDL cholesterol is viewed as a surrogate for apolipoprotein (Apo)B, an alternate end point of treatment. The present analysis of the previously reported Simvastatin plus Fenofibrate for Combined Hyperlipidemia (SAFARI) trial assessed the associations of non-HDL cholesterol and LDL cholesterol with ApoB levels in patients with combined hyperlipidemia treated with combination simvastatin (20 mg) and fenofibrate (160 mg) or simvastatin monotherapy (20 mg). The correlations of these factors were analyzed in the overall modified intent-to-treat population (n = 594) and in patient subgroups stratified by triglyceride (TG) tertiles. Simvastatin plus fenofibrate and simvastatin alone significantly reduced LDL cholesterol, TG, non-HDL cholesterol and ApoB levels and non-HDL cholesterol/ApoB ratio (p < or =0.0004), regardless of the TG level. The greatest reductions occurred with combination treatment. The baseline levels of non-HDL cholesterol and LDL cholesterol correlated highly with ApoB and were stronger in the lower TG tertiles than in the higher TG tertiles. After 12 weeks, the correlations had changed little with simvastatin monotherapy but had increased substantially with combination therapy and were most improved at high TG levels. In conclusion, these results suggest that both non-HDL cholesterol and ApoB provide similar information in relation to treatment response in patients with combined hyperlipidemia and hypertriglyceridemia, and that non-HDL cholesterol is a good indicator of ApoB-containing lipoproteins, supporting its recommended use as a secondary therapeutic target in these patients.
机译：指南建议在高甘油三酯血症患者达到低密度脂蛋白（LDL）胆固醇目标后，将非高密度脂蛋白（non-HDL）胆固醇作为治疗的次要目标;非HDL胆固醇被视为替代载脂蛋白（Apo）B的替代品。先前报道的辛伐他汀联合非诺贝特治疗合并性高脂血症（SAFARI）试验的当前分析评估了辛伐他汀（20 mg）和非诺贝特（160 mg）合并治疗的高脂血症合并非高脂血症患者中非HDL胆固醇和LDL胆固醇与ApoB水平的相关性或辛伐他汀单一疗法（20毫克）。这些因素的相关性在总体改良意向治疗人群（n = 594）和以甘油三酸酯（TG）三元组分层的患者亚组中进行了分析。单独使用辛伐他汀加非诺贝特和辛伐他汀可显着降低LDL胆固醇，TG，非HDL胆固醇和ApoB水平以及非HDL胆固醇/ ApoB比（p <或= 0.0004），而与TG水平无关。减少最大的是联合治疗。非高密度脂蛋白胆固醇和低密度脂蛋白胆固醇的基线水平与ApoB高度相关，并且在较低TG三分位数中比在较高TG三分位数中更强。 12周后，辛伐他汀单药治疗的相关性几乎没有改变，但联合治疗显着增加，在高TG水平下改善最大。总之，这些结果表明，非高密度脂蛋白胆固醇和ApoB在合并高脂血症和高甘油三酯血症的患者中提供与治疗反应相关的相似信息，并且非高密度脂蛋白胆固醇是含ApoB脂蛋白的良好指标，支持其推荐使用作为这些患者的次要治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号